Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31374634 | 0.84 | KDM1A (0.50) | PRCPGAACYP3A4CYP2D6RECQL | |
| SCHEMBL627815 | 0.84 | PRCP (0.49) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL9464912 | 0.83 | PRCP (0.66) | PRCPGAAMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL11810112 | 0.81 | GAA (0.67) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL1563035 | 0.81 | PRCP (0.46) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL1563034 | 0.81 | PRCP (0.46) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL11855708 | 0.80 | PRCP (0.49) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL8222451 | 0.80 | PRCP (0.47) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL10974810 | 0.80 | PRCP (0.45) | PRCPGAAMEN1KMT2ACYP3A4 | |
| SCHEMBL11034324 | 0.80 | PRCP (0.62) | PRCPGAAMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116546990-B | CD73 inhibitor and pharmaceutical application thereof | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| CN-117683029-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2024-01-25 | — | — | US | disclosed |
| CN-117430601-A | Bcl-2 inhibitors | 百济神州有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117362661-A | Hyperbranched carbon-nitrogen heterocyclic resin and resin composition, prepreg, circuit substrate and printed circuit board thereof | 浙江华正新材料股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| EP-1341765-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| EP-0801067-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1252166-A1 | OLEFIN POLYMERIZATION COCATALYSTS DERIVED FROM GROUP-15 CATIONIC COMPOUNDS AND PROCESSES USING THEM | EXXON CHEMICAL PATENTS INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002046164-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001042249-A1 | OLEFIN POLYMERIZATION COCATALYSTS DERIVED FROM GROUP-15 COMPOUNDS AND PROCESSES USING THEM | EXXON CHEMICAL PATENTS INC. (US) | 2001-06-14 | — | — | WO | disclosed |
| US-6174896-B1 | MUSCARINIC RECEPTOR ANTAGONISTIC ACTIVITY; FOR THERAPY AND PROPHYLAXIS FOR UROLOGIC DISEASES, RESPIRATORY DISEASES OR DIGESTIVE DISEASES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-6017927-A | Quinuclidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0801067-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
| EP-0257591-A2 | Process for preparing diphenylalkene derivatives | KANZAKI PAPER MANUFACTURING CO., LTD. (JP) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027158-A1 | High affinity small molecule C5a receptor modulators | C3AR1, C5AR1, C5AR2 | PRCP 1950/4885GAA 4835/4885MEN1 4152/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | PRCP 2363/4885GAA 1765/4885MEN1 3803/4885 |
| US-20240024346-A1 | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF | ENTPD5, NT5E, ENTPD1 | PRCP 1272/4885GAA 223/4885MEN1 1633/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | PRCP 2363/4885GAA 1765/4885MEN1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.